Lv3
328 积分 2023-06-02 加入
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2天前
已完结
A Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms
2天前
已完结
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study
2个月前
已完结
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial
4个月前
已完结
Single‐cell transcriptomic analysis uncovers intratumoral heterogeneity and drug‐tolerant persister in ALK‐rearranged lung adenocarcinoma
4个月前
已完结
Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer
4个月前
已完结
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer
6个月前
已关闭
驱动基因阳性晚期非小细胞肺癌免疫治疗专家共识 2023 版
8个月前
已完结
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
8个月前
已完结
皖公网安备34019202002308
